Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $70
Definium Therapeutics (NASDAQ:DFTX) Q3 Loss Narrower as Pipeline Momentum Builds
Loading...